Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial

COVID-19 is an abnormal host response to the SARS-CoV-2 infection, which is associated with endothelial dysfunction and multi-organ failure. Atorvastatin has been proposed to reduce COVID-19 severity and morta...

Source: Respiratory Research - February 22, 2024 Category: Respiratory Medicine Authors: Naglaa Hamdi Eltahan, Neamat Hamdy Elsawy, Kholoud M. Abdelaaty, Amal Salah Elhamaky, Ahmed H. Hassan and Moataz Maher Emara Tags: Research Source Type: research